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a  b  s  t  r  a  c  t
Despite  WHO  recommendations  about  the  A/California/7/2009/H1N1-like  virus  vaccination,  studies  eval-
uating its  possible  inﬂuence  on  clinical  manifestations  and  autoantibody  proﬁle  in primary  Sjögren’s
syndrome  (SS)  are  scarce.  The  aim  of  this  study  was  to evaluate  the possible  inﬂuence  of  the  unadjuvanted
A/California/7/2009/H1N1-like  virus  vaccination  on clinical  manifestations  and  autoantibody  proﬁle  in  SS
in the short/long-term.  Thirty-six  SS  patients  (The  American-European  Consensus  Group  Criteria,  2002)
and 36 healthy  controls  with  comparable  mean  age  and  gender  were  evaluated  before  and  21-days  after
this vaccination  regarding  seroprotection/seroconversion,  factor  increase  in  geometric  mean  titer  (FI-
GMT) and  side  effects.  New  onset  of  disease  ﬂares  and  autoantibody  proﬁle  [antinuclear  antibodies,
anti-dsDNA,  anti-Ro(SSA)/La(SSB),  anti-RNP/anti-Sm,  rheumatoid  factor,  anti-alpha-fodrin,  anticardi-
olipin  and  anti-beta2-glycoprotein-I]  were  assessed  before,  21-days  and  1-year  after  vaccination.  Patients
and controls  had  similar  rates  of  seroconversion  (77.8  vs. 69.4%,  p  = 0.42),  seroprotection  (83.3  vs. 72.2%,
p  = 0.26)  and  FI-GMT  (p = 0.85).  Disease  duration,  prednisone  (2.1 ±  4.9 mg/day),  methotrexate  and  aza-
thioprine  did  not  affect  seroconversion  (p > 0.05).  Regarding  short-term,  no change  in the  frequency  or
levels of  autoantibodies  was  observed  (p > 0.05)  and  only  mild  side  effects  were  reported  in  comparable
rates  to controls  (p  > 0.05).  During  1-year  follow-up,  the  frequency  of  new  disease  ﬂares  was  similar  to
the previous  year  (11  vs.  19%,  p = 0.51),  and  four  patients  developed  positivity  to one  of  the  following
speciﬁcities:  anti-Ro(SSA)/anti-La/(SSB),  anti-alpha-fodrin,  or  IgM  anticardiolipin.  None  developed  spe-
ciﬁc  lupus  autoantibodies.  Of  note,  a signiﬁcant  increase  in  the  mean  levels  of  anti-Ro/SSA  (p = 0.0001)  and
anti-La/SSB  (p = 0.002)  was  detected  after  1-year  with  no  change  in the  other  autoantibodies.  This  is the
ﬁrst study  indicating  that inﬂuenza  A(H1N1)pdm09  vaccine  induces  long-term  changes  in autoantibody
proﬁle  restricted  to  SS  spectrum  without  a deleterious  effect  in disease  course.. Introduction
Primary Sjögren’s syndrome (SS) is a chronic autoimmune dis-
ase characterized primarily by involvement of the exocrine glands,
eading to sicca syndrome. Multiple organs may  also be affected,
ausing a highly variable spectrum of clinical manifestations. Most
atients have less severe extraglandular symptoms such as fatigue,
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polyarthralgia and diffuse myalgia, while others develop serious
systemic impairments such as pneumonitis, vasculitis, peripheral
neuropathy, glomerulonephritis, optic neuritis, multiple sclerosis-
like disease and even lymphoma [1].  The etiology is unknown,
but the autoimmune nature of SS is supported by the production
of multiple circulating autoantibodies [2].  Anti-Ro/SSA and anti-
La/SSB are detected in up to 90% and 60% of SS patients, respectively
[2], and they are included in the disease classiﬁcation criteria [3].
As a consequence of multiple systemic affections, it is often
Open access under the Elsevier OA license.necessary to use high doses of glucocorticoids, immunosuppress-
ive drugs and biological agents for the treatment of SS patients
[4]. Indeed, it is relevant that infections, particularly respiratory,
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his disease [5–7], and vaccination is the most effective preventive
easure to control virus dissemination and to reduce associated
omplications [8].  Pandemic inﬂuenza occurs repeatedly, H1N1
Spanish ﬂu, 1918), A/H2N2 (Asian inﬂuenza, 1957), A/H3N2 (Hong
ong ﬂu, 1968), H1N1 (Swine ﬂu, 1976; Russian ﬂu, 1977) strains
nd A/California/7/2009 [A(H1N1)pdm09] [9],  and it is of partic-
lar concern for immunosuppressed patients, who may  be very
xposed to this infection. Indeed, immunocompromised patients
ave indications to receive vaccine for seasonal and pandemic
nﬂuenza according to the European League Against Rheumatism
10] and the 2010 Recommendations of the Advisory Committee
n Immunization Practices [11], but data regarding its immuno-
enicity and disease safety in SS are scarce. In fact, the only two
vailable published reports including SS patients focused on an
verall analysis of several autoimmune rheumatic diseases (ARD)
nd evaluated short-term (n = 36) [12] and six months (n = 23) [13]
afety and immunogenicity of A(H1N1)pdm09 inﬂuenza [12] and
easonal and/or pandemic inﬂuenza vaccination [13]. Both studies
howed adequate seroconversion rate and mild vaccine side effects
n ARD patients [12,13], however without a particular evaluation
f the SS group [12,13]. In this regard, a control group of healthy
ndividuals with comparable mean ages and gender is an essential
arameter [14] not fulﬁlled in the previous large cohort study of
RD particularly for SS patients [12]. In addition, the effect of vac-
ine on disease itself was not evaluated and this is a relevant issue
or patients with autoimmune genetic background such as those
ith SS, since the adjuvanted and non-adjuvanted A/H1N1 vaccines
n the general population were associated with the development
f various immunological disorders such as Guillain–Barré syn-
rome, acute encephalomyelitis, thrombocytopenia and vasculitis
15].
In addition, there are no data on the possible inﬂuence of the
nadjuvanted A/California/7/2009/H1N1-like virus immunization
n the autoantibody proﬁle in SS patients. In this regard, increased
erum levels of anticardiolipin antibodies (aCL) were observed in
atients with systemic lupus erythematosus (SLE) up to one year
fter seasonal inﬂuenza immunization [16]. Likewise, the seasonal
nd/or pandemic inﬂuenza vaccine induced the production of anti-
xtractable nuclear antigen (anti-ENA) antibodies in ARD patients;
evertheless a SS group was not analyzed [17]. Thus, the aim
f the present study was to evaluate short/long-term effects of
nadjuvanted inﬂuenza A/California/7/2009/H1N1-like virus vac-
ination on clinical manifestations and autoantibody proﬁle in
S.
. Patients and methods
For this study, all SS patients and healthy controls had been
ecruited during the Public Health Pandemic Inﬂuenza Vaccination
ampaign between March and April 2010 in a large, prospec-
ive rheumatic disease cohort study conducted at a single center,
heumatology Division, Hospital das Clínicas da Faculdade de
edicina da Universidade de São Paulo – HCFMUSP, São Paulo,
razil, (described in detail elsewhere [12]). The three male SS
atients of our cohort did not respond to this call.
The study was approved by the local institutional review board,
nd all participants signed the informed consent. The trial was  reg-
stered at clinicaltrials.gov under NCT01151644.
.1. Patients and healthy individualsThirty-six female SS patients (according to The American-
uropean Consensus Group Criteria [3]) aged >18 years (mean age:
5.6 ± 14.7 years) with stable disease (without active neurological
r renal affections, and without current vasculitis) were selected1 (2013) 1793– 1798
and regularly followed for one year at the out-patient Sjögren’s
Syndrome Clinic (Rheumatology Division, HCFMUSP). Patients with
history of multiple sclerosis-like disease or Guillain–Barré syn-
drome were excluded. Thirty-six healthy females with comparable
age (52.3 ± 11.3 years-old, p = 0.29) to the patients were included.
2.2. Vaccine
The A(H1N1)pdm09 vaccine, a novel, monovalent, unadju-
vanted, inactivated and split-virus vaccine, was  produced by
Butantan Institute/Sanoﬁ Pasteur (São Paulo, Brazil). The active
substance is a split, inactivated inﬂuenza virus containing anti-
gens equivalent to the A/California/7/2009 (H1N1) virus-like strain
(NYMCx-179A), one of the candidate reassortant vaccine viruses
recommended by the WHO. The vaccine was  propagated in embry-
onated chicken eggs, with the same standard techniques that are
used for the production of seasonal trivalent inactivated vaccines,
and it was presented in 5-ml multidose vials, with thimerosal added
as a preservative (15 g/0.5 ml  dose).
2.3. Study design
Participants were assessed immediately before and 21-days
after vaccination to determine seroprotection and seroconversion
by haemagglutination inhibition assay (HIA) (Adolfo Lutz Insti-
tute, São Paulo, Brazil). Side effects (local pain, fever, arthralgia
and ﬂu symptoms) were also evaluated through a diary card.
Disease ﬂares were evaluated in all patients retrospectively 1-
year prior and prospectively 1-year after vaccination (n = 36).
Analysis of autoantibody proﬁle included antinuclear antibodies
(ANA), anti-double-stranded DNA (anti-dsDNA), anti-Ro/SSA, anti-
La/SSB, anti--fodrin, anti-U1RNP, anti-Sm, rheumatoid factor (RF),
anticardiolipin (aCL) and anti-2-glycoprotein-I (anti-2GPI) anti-
bodies, and it was  performed in patients immediately before,
21-days (n = 36) and 1-year (n = 20) of vaccination. During the vac-
cination campaign, healthy volunteers were followed only in the
short-term (21-days), thus analysis of autoantibodies 1 year after
immunization was performed only for SS patients.
2.4. Vaccination
All subjects were vaccinated with the pandemic inﬂuenza
vaccine (A/California/7/2009/H1N1-like virus), Butantan Insti-
tute/Sanoﬁ Pasteur). A single intramuscular dose (0.5 ml) of
15 g haemagglutinin antigen, speciﬁc for the A/California/7/2009
(H1N1)-like virus, was  administered.
2.5. Safety assessments
A 21-day diary card was given to each participant at study
entry with a list of 13 solicited adverse reactions. This written card
included local reactions (pain, redness, swelling and itching) and
systemic adverse events such as arthralgia, fever, headache, myal-
gia, sore throat, cough, diarrhea, rhinorrhea and nasal congestion.
Participants were required to return their diary cards at the end
of the follow-up period (21 days after vaccination). All local reac-
tions were considered to be related to the A(H1N1)pdm09 vaccine.
Severe side effects were deﬁned as those requiring hospitalization
or leading to death. In addition, all SS patients were also evaluated
regarding new onset of disease ﬂares (parotiditis, arthritis, vasculi-
tis, pneumonitis or neurological disorders) retrospectively 1-year
prior and prospectively 1-year after vaccination. Medical charts
were extensively reviewed for additional clinical and treatment
data.























































Immunogenicity and side effects of A(H1N1)pdm09 vaccine – 21 days in SS patients
and  controls.
SS n = 36 Controls n = 36 p-value
Age, years [mean ± SD] 55.6 ± 14.7 52.3 ± 11.3 0.29
Female [n (%)] 36 (100) 36 (100) –
Seroprotection [n (%)]
Before vaccination 4 (11.1) 3 (8.3) 1.00
After vaccination 30 (83.3) 26 (72.2) 0.26
Seroconversion (%) 28 (77.8) 25 (69.4) 0.42
Side effects (%)
Local pain 5 (13.9) 4 (11.1) 1.00
Fever 2 (5.6) 0 0.49
Arthralgia 6 (16.7) 4 (11.1) 0.74
Headache 6 (16.7) 5 (13.9) 1.00
Rhinorrhea 3 (8.3) 5 (13.9) 0.71
Sore throat 3 (8.3) 8 (8.3) 1.00
Cough 7 (19.4) 3 (8.3) 0.31S.G. Pasoto et al. / Vac
.6. Laboratory assays
Blood samples from patients and controls were collected at
aseline and 3 weeks after vaccination for evaluation of the
(H1N1)pdm09 vaccination serological response. Sera were stored
t −70 ◦C and the two samples from each patient or control were
ested in parallel in the same plate. The immunogenicity of the
/California/7/2009 (H1N1)-like virus vaccine was  evaluated with
he use of a haemagglutination inhibition assay (HIA) at the Adolfo
utz Institute. Samples were also collected from twenty patients 1
ear after vaccination for evaluation of the proﬁle of autoantibodies
n the long term. The three samples from each patient (immediately
efore, 21-days and 1-year) of vaccination were tested in parallel
n the same plate for all autoantibody determinations listed below.
.7. Haemagglutination inhibition assay (HIA)
The inﬂuenza virus antigen used in this study was  the
/California/7/2009 (H1N1) supplied by the Butantan Institute.
irus concentrations were determined by haemagglutinin antigen
itration, and the HIA test was performed after removing natu-
ally occurring, non-speciﬁc inhibitors from the sera, as previously
escribed [18]. The A(H1N1)pdm09 vaccine immunoresponse was
valuated by determining levels of antibodies by haemagglutina-
ion inhibition. Anti-H1N1 titers were determined by inﬂuenza HIA.
he percentages of seroprotection (SP) (titer ≥1:40) and serocon-
ersion (SC) (a pre-vaccination titer <1:10 and a post-vaccination
IA titer ≥1:40 or pre-vaccination titers ≥1:10 and a ≥4-fold
ise post-vaccination), geometric mean titers (GMTs) and factor
ncreases (FIs) in GMTs were calculated [12].
.8. Autoantibodies
For the evaluations of several autoantibodies, three samples
rom each patient (immediately before, 21-days and 1-year after
accination) were tested in the same assay and applied in dupli-
ates. Antinuclear and anti-dsDNA antibodies were detected by
ndirect immunoﬂuorescence using as substrates HEp-2 cells or
rithidia luciliae, respectively (INOVA Diagnostics Inc., San Diego,
SA) [19]. Serum levels of anti-Ro/SSA, anti-La/SSB, anti-U1RNP
nd anti-Sm antibodies were determined by ELISA with the puriﬁed
ntigens according to manufacturer’s instructions (INOVA Diagnos-
ics Inc., San Diego, USA) [20]. Concentrations of anti-alpha-fodrin
ntibodies (IgG and IgA) were also measured by ELISA with the puri-
ed protein (ORGENTEC Diagnostika GmbH, Mainz, Germany) [21].
heumatoid factor (IgM-RF) was measured by ELISA (INOVA Diag-
ostics Inc., San Diego, USA). Serum antiphospholipid antibodies
ere also evaluated. IgG and IgM anticardiolipin antibodies (aCL)
ere tested by ELISA as previously described (INOVA Diagnostics
nc., San Diego, USA) [22]. IgG and IgM anti-beta2-glycoprotein-
 (anti-2GPI) were measured by ELISA (ORGENTEC Diagnostika
mbH, Mainz, Germany) as previously outlined [23].
.9. Statistical analysis
Comparison between two groups (SS patients vs. healthy con-
rols and SS patients with A(H1N1)pdm09 seroconversion vs. SS
atients without seroconversion) was conducted using Student’s
 test or Mann–Whitney U test for continuous variables and Chi-
quared test or Fisher’s exact test for categorical variables when
pplicable. For analysis comparing multiple data of the same group,
ne-way repeated measures analysis of variance (ANOVA) for
ontinuous data and McNemar’s test for categorical data were per-
ormed. Results are shown as a proportion, or mean ± standardSputum 4(11.1) 3 (8.3) 1.00
SS = primary Sjögren’s syndrome; n = number of patients; SD = standard deviation.
deviation (SD). Only two-tailed tests were applied. p-values <0.05
were considered to be statistically signiﬁcant.
3. Results
3.1. Short-term evaluation
3.1.1. Immunogenicity and safety of A(H1N1)pdm09 vaccine in
patients and controls
All SS patients and controls were female, with comparable mean
ages (55.6 ± 14.7 vs. 52.3 ± 11.3 years-old, p = 0.29). Pre-vaccination
seroprotection rates (11.1 vs. 8.3%, p = 1.00), seroconversion (77.8
vs. 69.4%, p = 0.42), and seroprotection after immunization (83.3 vs.
72.2%, p = 0.26) were similar in patients and controls, respectively
(Table 1). GMT  before [8.9 (6.5–12.3) vs. 8.1 (6.2–10.5), p = 0.96]
and after immunization [95.1 (60.4–149.8) vs. 89.8 (57.9–139.2),
p = 0.791], and FI-GMT [10.7 (6.7–16.9) vs. 11.1 (7.1–17.3), p = 0.85]
were also comparable in patients and controls, respectively.
Regarding short-term (21-days period) side effects, only mild reac-
tions related to the vaccine were observed in comparable rates in
patients and healthy individuals (p > 0.05) (Table 1).
3.1.2. Inﬂuence of clinical features and therapy on
A(H1N1)pdm09 vaccine seroconversion (SC)
In SS patients, seroconversion rate was not affected by disease
duration (p = 0.59), use of glucocorticoid (p = 0.16), methotrexate
(p = 0.65), antimalarial (p = 0.68), azathioprine (p = 0.21), or con-
comitant use of glucocorticoid and immunosuppressive drugs
(p = 0.31) (Table 2).
3.1.3. Short-term A(H1N1)pdm09 vaccine effects on disease ﬂares
and autoantibody proﬁle
None of the SS patients had disease ﬂares and no patient had
new positive tests or increased titers of ANA, anti-dsDNA, anti-
U1RNP/Sm, anti-Ro(SSA)/La(SSB), RF, anti--fodrin, aCL or a2GP1
(p > 0.05).
3.2. Long-term A(H1N1)pdm09 vaccine effects on disease ﬂares
and autoantibody proﬁle
3.2.1. Disease ﬂares 1-year prior and 1-year after vaccination
The prospective long-term evaluation of SS patients revealed
that 11% had new disease ﬂares during the 1-year period, but the
rate of new ﬂares was similar to the previous year (19%, p = 0.51)
(Table 3).
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Table  2





SC− (n = 8)
p-value
Age, years [mean ± SD] 54.2 ± 13.2 60.5 ± 17.7 0.29
Disease duration, years [mean ± SD] 10.6 ± 5.4 9.4 ± 4.6 0.59
Treatment
Prednisone [n (%)] 8 (28.6) 0 0.16
-dose, mg/day [mean ± SD] 2.1 ± 4.9 0 0.32
-range, mg/day 0–20 – –
Antimalarial drugs [n (%)] 8 (28.6) 3 (37.5) 0.68
Immunosuppressive agents 11 (39.3) 3 (37.5) 1.00
Azathioprine [n (%)] 2 (7.1) 2 (25) 0.21
-dose, mg/day [mean ± SD] 6.3 ± 23.2 25 ± 46.3  0.44
-range, mg/day 0 –100 0–100 –
Methotrexate [n (%)] 8 (28.6) 1 (12.5) 0.65
-dose, mg/week (mean ± SD) 4.1 ± 6.7 2.2 ± 5.8 0.57
-range, mg/week 0 –20 0–17.5 –
Mycophenolate mofetil [n (%)] 1 (3.6) 0 1.00
Prednisone + immunosuppressive
agents (%)
7 (25) 0 0.31
Without any of the above
medications (%)






























SS = primary Sjögren’s syndrome; SC = seroconversion; n = number of patients;
D  = standard deviation.
.2.2. Autoantibody proﬁle prior and 1-year after vaccination
In the long-term, 4/20 (20%) SS patients presented new positive
ests: one patient became positive for anti-Ro/SSA, another for anti-
a/SSB, one became positive for IgA anti-alpha-fodrin, and the last
atient for IgM anticardiolipin (with levels >40 MPL). None devel-
ped lupus speciﬁc autoantibodies. Of note, comparing antibody
evels at study inclusion, at 21-days and 1-year after vaccina-
ion, signiﬁcant increases in the levels of anti-Ro/SSA (100.0 ± 40.8
s. 100.9 ± 40.3 vs. 114.1 ± 40.1 U, respectively; p = 0.0001) and
nti-La/SSB (60.8 ± 42.0 vs. 60.5 ± 41.9 vs. 72.9 ± 47.2, respectively;
 = 0.002) were observed after 1 year, whereas no change was
etected for other antibodies speciﬁcities investigated (Table 4).
. Discussion
This is the ﬁrst study to indicate that inﬂuenza A(H1N1)pdm09
accine induces long-term changes in autoantibody proﬁle
estricted to SS spectrum without a deleterious effect in disease
ourse. The long-term evaluation was a relevant aspect of this
tudy, since increasing levels of autoantibodies induced by vacci-
ation was a late phenomenon. In fact, a three months evaluation
f autoantibody proﬁle in A(H1N1)pdm09 immunization has not
bserved increased antibody levels in SLE patients [24], as also
emonstrated herein for the 21-days assessment. We  did not
etect the occurrence of serious vaccine short-term adverse events
nd demonstrated adequate seroconversion and seroprotection
ates particularly in SS. Our ﬁnding is reinforced by the comparable
ean ages and gender in the groups of SS patients and healthy
able 3









Parotiditis [n (%)] 3 (8.3) 2 (5.6) 1.00
Arthritis [n (%)] 6 (16.7) 2 (5.6) 0.26
Cutaneous vasculitis [n (%)] 1 (2.8) 0 1.00
Pneumonitis [n (%)] 1 (2.8) 2 (5.6) 1.00
Neurological disorders [n (%)] 0 0 –
S = primary Sjögren’s syndrome; n = number of patients.1 (2013) 1793– 1798
individuals, an essential parameter [14] not fulﬁlled in our previous
large cohort study of autoimmune rheumatic diseases for these
particular group of patients [12]. Glucocorticoid did not have a
deleterious effect in vaccine humoral response probably related
to the use of low doses of this drug. Indeed, doses higher than
20 mg/day were associated with a diminished A(H1N1)pdm09
vaccine antibody production in rheumatoid arthritis (AR) and
systemic lupus erythematosus (SLE) [25,26]. Unlike evaluations
of AR and SLE patients [25–27],  immunosuppressive agents did
not reduce vaccine immunogenicity, but the small representation
of patients under this therapy in the present study hampers the
interpretation of this ﬁnding. Vaccine did not trigger disease’s
exacerbations, since the frequencies of parotiditis, arthritis, vas-
culitis, and pneumonitis at 1-year follow-up were similar to the
previous year. Additionally, our data suggest long-term vaccine
safety in an autoimmune rheumatic disease, with no cases of
neurological disorders such as Guillain–Barré syndrome, which
was described months after immunization mainly with adjuvanted
pandemic inﬂuenza vaccine in the general population [15].
The main limitation of our study is the evaluation of a group
of SS patients with peculiar features, i.e. with stable disease and
using low doses of glucocorticoids and immunosuppressant drugs.
In contrast, in systemic lupus erythematosus (SLE), there are
published data indicating that the unadjuvanted A(H1N1)pdm09
vaccine is safe in patients with active disease and using high doses
of prednisone and immunosuppressants, but with signiﬁcantly
impaired immunogenicity [26].
Another important concern regarding vaccines is that they can
occasionally stimulate autoantibody production or even a recently
deﬁned syndrome known as autoimmune/inﬂammatory syndrome
induced by adjuvants (ASIA) [28]. In this regard, a case of primary
Sjögren’s syndrome following adjuvant inﬂuenza A(H1N1)pdm09
vaccination was described [29]. Symptoms started seven days after
the immunization, with development of polyarthralgia, dry mouth,
dry eyes, positive antinuclear antibodies, positive anti-Ro/SSA anti-
body and the presence of lymphocytic inﬁltrates in the salivary
glands [29]. Analysis of samples from labial tissues using poly-
merase chain reaction method (PCR) showed the absence of the
inﬂuenza A(H1N1)pdm09 RNA, indicating that there was  no direct
viral presence in the salivary glands [29]. The authors hypothe-
size that vaccine antigens could trigger the immune system by
different mechanisms such as molecular mimicry, epitope spread-
ing and polyclonal activation, leading to the outbreak of Sjögren’s
syndrome manifestations and the appearance of antinuclear and
anti-Ro/SSA antibodies [29]. In this regard, we  chose to use solely
the non-adjuvanted vaccine because SS patients have theoreti-
cally a genetic predisposition for the development of autoimmune
phenomena [1]. Furthermore, according to a systematic review on
vaccination in patients with autoimmune rheumatic diseases car-
ried by European League Against Rheumatism (EULAR), the safety
regarding adjuvants in these diseases remains to be deﬁned [30].
Importantly, the changes in autoantibody proﬁle observed
herein were restricted to SS spectrum and mainly in the levels
of anti-Ro(SSA)/La(SS-B), raising the hypothesis that this antibody
production may  be a consequence of molecular mimicry. In this
aspect, it is interesting that it was  observed molecular mimicry
between the antigen Ro and the Epstein–Barr virus (EBV) protein
EBNA-1 [31,32].
Increased serum levels of these antibodies observed herein were
not, however, associated with disease ﬂares, as shown by clinical
evaluation. Indeed, titers of anti-Ro antibodies may  ﬂuctuate dur-
ing the course of the illness in both SLE and SS patients, but these
changes were not associated with disease ﬂares, with the exception
of some patients with skin vasculitis [33]. A similar phenomenon
was observed in SLE patients six months after non-adjuvanted
A(H1N1)pdm09 immunization, with signiﬁcantly higher levels of
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Table 4
Autoantibody proﬁle immediately before, 21-days and 1-year after A(H1N1)pdm09 vaccination in SS patients.
Before n = 20 21-Days after n = 20 1-Year after n = 20 p-value
Anti-Ro/SSA
-n (%) 18 (90) 18 (90) 19 (95) 1.00
-Serum levels [U, mean ± SD] 100.0 ± 40.8 100.9 ± 40.3 114.1 ± 40.1 0.0001
Anti-La/SSB
-n  (%) 12 (60) 12 (60) 13 (65) 1.00
-Serum levels [U, mean ± SD] 60.8 ± 42.0 60.5 ± 41.9 72.9 ± 47.2 0.002
Anti-U1RNP
-n  (%) 6 (30) 6 (30) 5 (25) 1.00
-Serum levels [U, mean ± SD] 31.0 ± 25.2 31.1 ± 28.0 30.7 ± 31.5 0.91
Rheumatoid factor IgM
-n (%) 12 (60) 12 (60) 12 (60) –
-Serum levels [U, mean ± SD] 105.9 ± 129.3 102.1 ± 119.9 90.8 ± 97.8 0.20
Anti--fodrin IgG
-n (%) 1 (5) 1 (5) 1 (5) –
-Serum levels [U, mean ± SD] 6.8 ± 6.3 6.8 ± 5.6 6.7 ± 6.2 0.85
Anti--fodrin IgA
-n (%) 1 (5) 1 (5) 2 (10) 1.00
-Serum levels [U, mean ± SD] 6.9 ± 2.7 6.9 ± 2.2 7.6 ± 6.9 0.67
aCL  IgG
-n (%) 0 0 0 –
-Serum levels [GPL, mean ± SD] 8.8 ± 5.0 8.3 ± 4.5 8.1 ± 4.1 0.48
aCL  IgM
-n (%) 0 0 1 (5) 1.00
-Serum levels [MPL, mean ± SD] 10.9 ± 8.5 11.3 ± 8.2 10.7 ± 10.7 0.90
a2GPI  IgG
-n (%) 0 0 0 –
-Serum levels [U, mean ± SD] 7.2 ± 2.5 7.1 ± 2.9 6.4 ± 1.9 0.06
a2GPI  IgM
-n (%) 1 (5) 1 (5) 1 (5) –
-Serum levels [U, mean ± SD] 11.5 ± 22.3 13.6 ± 29.2 10.5 ± 15.5 0.62
SS = primary Sjögren’s syndrome; n = number of patients; SD = standard deviation.
aCL = anticardiolipin antibody; a2GPI = anti-2-glycoprotein-I antibody.


















[2GPI  > 20 U.
nti-Sm compared to baseline, but without clinical consequences
25].
In conclusion, inﬂuenza A(H1N1)pdm09 vaccine stimulates
ong-term production of SS related autoantibodies without a rel-
vant change in clinical course. The additional observation of an
dequate seroconvertion and seroprotection rates supports its rec-
mmendation in this disease.
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